---
schemaVersion: murph.commons.page.v1
entityType: protocol_variant
key: protocol_variant:vitamin-d-supplementation/daily-vitamin-d3-supplementation
slug: protocols/vitamin-d-supplementation/daily-vitamin-d3-supplementation
title: Daily Vitamin D3 Supplementation
summary: Take a consistent daily oral vitamin D3 dose and use 25(OH)D lab feedback, safety screening, and confounder logs to test whether vitamin D status changes without overclaiming clinical benefits.
status: draft
quality: usable
hidden: true
aliases:
  - daily cholecalciferol
  - daily D3
  - daily oral vitamin D3
  - vitamin D3 daily supplementation
  - 25(OH)D lab-feedback experiment
categories:
  - supplements
  - nutrition
  - vitamin-d
  - biomarker-feedback
  - lab-guided
media:

  -
    kind: image
    relativePath: design-assets/hero-04.png
    mediaType: image/png
    caption: Daily Vitamin D3 Supplementation
relations:

  -
    type: parent_family
    target: experiment_family:vitamin-d-supplementation
  -
    type: primary_biomarker
    target: biomarker:serum-25-hydroxyvitamin-d
  -
    type: cites
    target: source_artifact:pmid-12499343
  -
    type: cites
    target: source_artifact:doi-10.17226-13050
  -
    type: cites
    target: source_artifact:doi-10.2903-j.efsa.2023.8145
  -
    type: cites
    target: source_artifact:pmid-38828931
lineage:
  relationship: root
  rationale: Drafted from vitamin-d-supplementation research outputs, canonical ledger, atomic findings, and section syntheses.
attribution:
  ownerType: murph
  note: Murph Health Commons
protocol:
  doseSignature: Daily · oral vitamin D3/cholecalciferol · low-risk adult wellness self-tracking only · commonly 800–1000 IU/day starting/maintenance range after negative safety screen unless clinician-directed · 8–12 week lab-feedback window
  target: Maintain or modestly raise serum 25(OH)D while staying below upper-intake safety boundaries and avoiding stacked supplement dosing.
  frequency:
    sessionsPerWeek: 7
    sessionsPerDay: 1
  interventionSessionsMinimum: 56
  interventionSessionsTarget: 84
  steps:
    - Before starting, review current vitamin D from all supplements, multivitamins, fortified products, and prescriptions; avoid stacking products that silently raise total daily intake.
    - Do not start this ordinary self-directed variant without clinician guidance if you have kidney disease or reduced kidney function; a history of kidney stones; high serum calcium, high urine calcium, hypercalcemia, hypercalciuria, hyperparathyroidism, or unexplained calcium/PTH abnormalities; sarcoidosis or another granulomatous-disease context; clinician warnings about vitamin D or calcium handling; pregnancy, trying to conceive, breastfeeding, or pediatric/adolescent use; diagnosed vitamin D deficiency or a prescribed repletion/loading plan; malabsorption, cystic fibrosis, bariatric surgery, short bowel, or intestinal-rehabilitation context; or use of calcitriol, alfacalcidol, paricalcitol, calcifediol, prescription/high-dose vitamin D, high-dose calcium products, or a medication plan where calcium or kidney-function changes would be clinically important.
    - Choose one oral cholecalciferol/D3 product with a clearly labeled IU dose and take it once daily with a consistent routine cue; this extraction did not support a specific meal, fat, morning, or evening timing instruction.
    - For a low-risk adult self-experiment after a negative safety screen, 800–1000 IU/day can be used as a conservative common starting/maintenance range; do not use this as treatment for diagnosed deficiency, do not chase a high 25(OH)D target, and treat 4000 IU/day as an adult upper-intake ceiling rather than a goal.
    - Record a baseline 25(OH)D value if available, plus the lab unit, date, season, latitude or travel context, sun/UV exposure, diet/fortified-food pattern, body-weight context, and current supplements.
    - Take the same daily dose for 8–12 weeks only while no stop condition is present, logging missed doses, extra doses, dose changes, product changes, new supplements or medications, calcium products, major sun/UV or travel changes, diet/fortified-food changes, and symptoms that could suggest calcium or kidney-stone issues.
    - Recheck 25(OH)D after the stable dosing window if you are using lab feedback. If risk factors, high dose, calcium co-use, symptoms, prior abnormal calcium/urine-calcium/kidney labs, or clinician-directed treatment are present, do not manage this as an ordinary wellness experiment; use clinician guidance and risk-based labs such as calcium, creatinine/eGFR, or urine calcium when clinically indicated.
  tips:
    - Same lab and units for baseline and follow-up 25(OH)D.
    - Log sun exposure, travel, diet, and supplement changes so the result is interpretable.
    - A missed day is a log entry, not a reason to double up unless clinician-directed.
    - Store away from children; avoid unlabeled compounded or repackaged products.
  keepInMind:
    - The strongest expected signal is a change in 25(OH)D, not guaranteed changes in symptoms, fractures, falls, infections, mood, fatigue, or cardiovascular outcomes.
    - Response varies by baseline 25(OH)D, body size, season, sun exposure, diet, ethnicity/population context, adherence, and assay differences.
    - Daily D3 is not the same protocol as D2, calcifediol, calcitriol/active analogues, UVB exposure, fortified-food trials, or intermittent high-dose bolus schedules.
    - Higher dose is not automatically better; safety boundaries and personal risk factors matter more than chasing a high biomarker value.
  logFields:
    - date
    - vitamin_d3_dose_iu
    - product_name
    - taken_yes_no
    - missed_or_extra_dose
    - other_vitamin_d_or_calcium_supplements
    - sun_or_uv_exposure_change
    - travel_or_latitude_change
    - diet_or_fortified_food_change
    - symptoms_or_adverse_events
    - 25ohd_lab_value_and_unit
  sessionFieldIds:
  - dose_taken
  - vitamin_d3_dose_iu
  - product_name
  stopConditions:
    - Symptoms suggesting hypercalcemia or kidney stone occur; seek urgent care for severe confusion, severe dehydration, persistent vomiting, inability to keep fluids down, severe flank pain, blood in urine, fever with stone symptoms, or rapidly worsening weakness.
    - Stop and seek clinician guidance if serum calcium is high, urine calcium is high, 25(OH)D is above the lab reference range or clinician concern threshold, kidney function worsens, kidney-stone symptoms occur, or a clinician tells you to stop.
    - Stop if a product error, recall, labeling concern, accidental high dose, compounded/repackaged product, or untracked supplement stack makes total vitamin D dose uncertain.
    - Pause if total vitamin D intake may exceed 4000 IU/day, or if you start calcium products, calcifediol, active vitamin D analogues, prescription/high-dose vitamin D, weekly/monthly/bolus/loading schedules, or medication changes requiring calcium/kidney review.
    - Do not continue unsupervised if a new kidney, calcium, urine-calcium, parathyroid, granulomatous, pregnancy/lactation, pediatric/adolescent, malabsorption/bariatric, clinician-flagged vitamin D/calcium risk, deficiency-treatment, or active-analogue context arises.
testPlans:

  -
    planId: 25ohd-lab-feedback-91d
    durationDays: 91
    baselineDays: 7
    interventionDays: 84
    primaryBiomarkerKey: biomarker:serum-25-hydroxyvitamin-d
    minimumAdherenceSessions: 56
    targetAdherenceSessions: 84
    notes:
      - Primary endpoint is baseline-to-follow-up 25(OH)D, preferably same lab and same unit.
      - The baseline week is for context capture; the dose-change signal usually needs weeks rather than days.
      - Secondary notes should capture adverse symptoms, supplement stacking, calcium intake changes, sun exposure, travel, and diet changes.
expectedSignalDescriptions:

  -
    biomarkerKey: biomarker:serum-25-hydroxyvitamin-d
    description: "Daily D3 supplies cholecalciferol for liver conversion into 25(OH)D, raising the follow-up lab when intake and absorption stay stable."
    expected: Likely rises
    expectedDirection: up
    estimatedChange:
      kind: absolute
      low: 8
      high: 14
      unit: ng/mL
      window: 8–12 weeks
      confidence: moderate
      basis: Direct 800–1000 IU/day D3 trials show roughly +20–35 nmol/L by 8–12 weeks, equivalent to about +8–14 ng/mL; response shifts with baseline level, body size, season, sun exposure, diet, adherence, and assay.
    protocolProminence: focus
experimentOnboarding:
  schemaVersion: "murph.commons.experiment-onboarding.v2"
  startIntent:
    displayPrompt: "Set up a daily vitamin D3 experiment with lab-feedback tracking and safety screening."
    intentSummary: "Run a daily D3 protocol with 25(OH)D as the primary endpoint."
  safetyScreen:
    dispositionIfAnyPositive: "clinician_guidance_before_unsupervised_start"
    mustAsk:
      - id: "kidney_disease_or_stones"
        prompt: "Do you have chronic kidney disease, reduced kidney function, abnormal creatinine/eGFR, or a history of kidney stones?"
        ifPositive: "clinician_guidance_before_unsupervised_start"
      - id: "high_calcium_or_parathyroid"
        prompt: "Have you had high serum calcium, high urine calcium/hypercalciuria, hypercalcemia, hyperparathyroidism, abnormal PTH/phosphorus in a kidney context, or unexplained calcium abnormalities?"
        ifPositive: "clinician_guidance_before_unsupervised_start"
      - id: "granulomatous_or_clinician_warning"
        prompt: "Do you have sarcoidosis, another granulomatous disease, or clinician warnings about vitamin D or calcium handling?"
        ifPositive: "clinician_guidance_before_unsupervised_start"
      - id: "clinician_repletion_or_abnormal_25ohd"
        prompt: "Are you treating diagnosed vitamin D deficiency, following a clinician-prescribed repletion/loading plan, or responding to a very low or above-range 25(OH)D result?"
        ifPositive: "clinician_guidance_before_unsupervised_start"
      - id: "calcium_stack_or_urine_calcium"
        prompt: "Are you taking calcium supplements, high-dose calcium antacids, calcium prescriptions, or have you had high urine calcium/hypercalciuria?"
        ifPositive: "clinician_guidance_before_unsupervised_start"
      - id: "malabsorption_bariatric_or_cf"
        prompt: "Do you have cystic fibrosis, fat malabsorption, short bowel, intestinal rehabilitation, Roux-en-Y or other bariatric surgery, or another absorption problem?"
        ifPositive: "clinician_guidance_before_unsupervised_start"
      - id: "non_daily_or_non_d3_variant"
        prompt: "Are you using D2, calcifediol, calcitriol, alfacalcidol, paricalcitol, UVB/sunlight treatment, fortified-food intervention, or a weekly/monthly/bolus/loading vitamin D schedule?"
        ifPositive: "clinician_guidance_before_unsupervised_start"
      - id: "pregnancy_or_pediatric"
        prompt: "Are you pregnant, trying to conceive, breastfeeding, or setting this up for a child or adolescent?"
        ifPositive: "clinician_guidance_before_unsupervised_start"
    stopIf:
      additionalConditions:
        - "possible_hypercalcemia_or_kidney_stone_symptoms"
        - "high_serum_calcium_or_high_urine_calcium"
        - "above_range_25ohd_or_clinician_concern_threshold"
        - "kidney_function_worsens"
        - "exceeds_upper_intake_ceiling_or_total_intake_unknown"
        - "switches_to_non_daily_or_non_d3_variant"
        - "product_error_recall_or_dose_uncertainty"
  setupSlots:
    - id: "daily_dose_iu"
      label: "Daily D3 dose in IU"
      question: "What daily vitamin D3 dose in IU will you use?"
      constraints:
        recommendedStartingRange: "800-1000 IU/day only for low-risk adults after negative safety screen"
        upperIntakeCeiling: 4000
        invalidIf:
          - "dose_iu <= 0"
          - "dose_iu > 4000"
          - "total_vitamin_d_from_all_sources_unknown"
          - "active_safety_screen_positive_without_clinician_guidance"
        onInvalid: "do_not_create_ordinary_protocol; route_to_clinician_guidance_or_separate_variant"
      target:
        object: "onboardingCapture"
        field: "setupAnswers.dailyDoseIu"
    - id: "product_name"
      label: "Product name"
      question: "Which D3 product will you use?"
      constraints:
        optional: true
      target:
        object: "onboardingCapture"
        field: "setupAnswers.productName"
    - id: "dose_time"
      label: "Dose time"
      question: "What time of day will you usually take it?"
      constraints:
        optional: true
      target:
        object: "onboardingCapture"
        field: "setupAnswers.doseTime"
    - id: "baseline_25ohd_known"
      label: "Baseline 25(OH)D known"
      question: "Do you have a baseline 25(OH)D result or plan to get one?"
      target:
        object: "onboardingCapture"
        field: "setupAnswers.baseline25ohdKnown"
    - id: "retest_plan"
      label: "Follow-up lab plan"
      question: "When will you recheck 25(OH)D?"
      options:
        - "eight_weeks"
        - "twelve_weeks"
        - "no_lab_planned_yet"
      constraints:
        optional: true
      target:
        object: "onboardingCapture"
        field: "setupAnswers.retestPlan"
    - id: "current_supplement_stack"
      label: "Current D/calcium supplements"
      question: "List other vitamin D, calcium, multivitamin, or prescription products you take."
      target:
        object: "onboardingCapture"
        field: "setupAnswers.currentSupplementStack"
  planDefaults:
    testPlanId: "25ohd-lab-feedback-91d"
    firstSessionGuidance: "After the safety screen is negative, total vitamin D intake is known, and the selected dose is within the adult ceiling, take the planned daily D3 dose once with your chosen routine cue, then log dose, product, supplement stack, calcium context, and any confounder changes."
  trackingHints:
    confounderFields:
      - "missed_or_extra_dose"
      - "other_vitamin_d_or_calcium_supplements"
      - "sun_or_uv_exposure_change"
      - "travel_or_latitude_change"
      - "diet_or_fortified_food_change"
      - "symptoms_or_adverse_events"
    notes:
      - "Ask for lab value, unit, and date when a baseline or follow-up 25(OH)D result is entered."
  supportHints:
    missedLogFollowupCopy: "Log missed D3 doses as context; do not double up just because a log was missed."
whyItWorks:
  - "## Daily D3 feeds the liver conversion that raises 25(OH)D\n\nOral cholecalciferol enters circulation and the liver hydroxylates it into 25-hydroxyvitamin D — the form measured by a standard vitamin D lab. Consistent daily dosing at 800–1000 IU raises serum 25(OH)D by roughly 8–14 ng/mL over 8–12 weeks in trials of healthy adults."
  - "## Response depends on where you start and how you live\n\nBaseline 25(OH)D, body size, season, latitude, sun exposure, skin pigmentation, diet, and adherence all shift the dose-response curve. A person starting low in winter gains more per IU than someone replete in summer. Murph treats this as a logged N-of-1 lab-feedback experiment, not a fixed-dose guarantee."
  - "## Safety boundaries outweigh dose chasing\n\n4000 IU/day is an adult upper-intake ceiling, not a target. Meta-analyses find increased hypercalcemia risk at 3200–4000 IU/day, and higher daily doses lower volumetric BMD in trial evidence. Kidney disease, stones, high calcium, supplement stacking, and active vitamin D analogues shift the safety posture further."
mechanismChain:
  -
    label: "Dose"
    content: "Daily oral cholecalciferol · 800–1000 IU typical start"
  -
    label: "Hepatic conversion"
    content: "Liver hydroxylates D3 into 25(OH)D; circulating level rises over weeks"
  -
    label: "Steady state"
    content: "8–12 weeks of consistent intake · serum 25(OH)D stabilizes at new level"
  -
    label: "Adaptation"
    content: "Vitamin D status shifts measurably; downstream calcium and bone metabolism gain substrate"
claims:

  -
    claimId: dose-implementation-001-direct-daily-d3-dose-response
    type: intervention_result
    text: Direct daily oral cholecalciferol evidence supports a dose-related increase in serum 25(OH)D over weeks. Extracted direct trials and syntheses include winter dose-response arms, 400-2000 IU/day arms, 800 IU/day and 1000 IU/day trials, and a European healthy-adult meta-analysis estimating a pooled serum 25(OH)D increase versus placebo. This supports daily D3 as a biomarker protocol, not as proof of broad clinical benefit.
    strength: high
    sourceKeys:
      - source_artifact:pmid-12499343
      - source_artifact:pmid-19064513
      - source_artifact:pmid-20089776
      - source_artifact:pmid-25694350
      - source_artifact:pmid-26037521
      - source_artifact:pmid-32365732
      - source_artifact:pmid-37764770
    caveats:
      - Primary endpoint is serum 25(OH)D, not symptoms, fractures, cardiovascular events, cancer, or other disease outcomes.
      - Dose-response slopes differ across trials and populations.
      - Some syntheses aggregate heterogeneous regimens and populations.
  -
    claimId: dose-implementation-002-800-to-1000-iu-range-with-target-caveats
    type: mixed_evidence
    text: For protocol implementation copy, 800-1000 IU/day can be presented as a common evidence-supported adult starting or maintenance range, but not as a guaranteed target-achieving dose. One postmenopausal-women trial found 800 IU/day raised 25(OH)D above 50 nmol/L in 97.5% of participants, an 800 IU/day winter RCT reported 94% reaching at least 50 nmol/L by study end, and a European meta-analysis modeled about 1000 IU/day to bring 95% of healthy adults to at least 50 nmol/L; however, a healthy Chinese low-baseline trial found that even 2000 IU/day did not bring 97.5% of participants to at least 50 nmol/L by 16 weeks.
    strength: moderate
    sourceKeys:
      - source_artifact:pmid-22431675
      - source_artifact:pmid-26037521
      - source_artifact:pmid-25694350
      - source_artifact:pmid-37764770
      - source_artifact:pmid-19064513
    caveats:
      - Thresholds such as 50 nmol/L and 75 nmol/L are not the same target.
      - Population, season, baseline status, and calcium co-supplementation can affect applicability.
      - This is implementation guidance for a self-experiment page, not a universal clinical dose prescription.
  -
    claimId: dose-implementation-003-response-modifiers-and-individualization
    type: association_not_causation
    text: Dose response should be described as individualized rather than one-size-fits-all: extracted evidence links response variability to baseline 25(OH)D, BMI/body weight or obesity, age, ethnicity or race-related strata, season/sun context, and chosen target threshold. Higher-target or higher-BMI contexts sometimes used or modeled higher daily doses, but those data should prompt biomarker-guided personalization rather than unsupervised dose escalation.
    strength: moderate
    sourceKeys:
      - source_artifact:pmid-18541590
      - source_artifact:pmid-22431675
      - source_artifact:pmid-26037521
      - source_artifact:pmid-32365732
      - source_artifact:pmid-33954783
      - source_artifact:pmid-36648947
      - source_artifact:pmid-31832878
      - source_artifact:pmid-39432764
      - source_artifact:pmid-27194308
    caveats:
      - Modifier evidence is not a validated dose calculator.
      - Some higher-dose studies used calcium co-supplementation or supervised target-seeking designs.
      - Ethnicity and race evidence is heterogeneous and should not be converted into deterministic dose rules.
  -
    claimId: dose-implementation-004-wash-in-and-evaluation-window
    type: design_guardrail
    text: Daily D3 response should be evaluated over weeks, not days. Extracted trials observed meaningful 25(OH)D changes at 4 weeks, 8-12 weeks, 16 weeks, and approximately 20-22 weeks; therefore a protocol page can reasonably tell users to keep dosing consistent and avoid judging the dose from short-term symptoms or a few days of use.
    strength: moderate
    sourceKeys:
      - source_artifact:pmid-17456248
      - source_artifact:pmid-26037521
      - source_artifact:pmid-25694350
      - source_artifact:pmid-12499343
      - source_artifact:pmid-19064513
      - source_artifact:pmid-31669447
    caveats:
      - Clinical deficiency treatment may require clinician-directed testing and different timing.
      - A biomarker check window is not evidence that symptoms should change on the same schedule.
      - Equilibrium timing can vary by dose, baseline status, season, and body size.
  -
    claimId: dose-implementation-005-default-formulation-oral-cholecalciferol
    type: design_guardrail
    text: The protocol should default to oral cholecalciferol/D3 and avoid claiming superiority for a specific consumer form. A 10 µg/day trial found no clear advantage between multivitamin tablets and fish-oil capsules, a 1000 IU/day study found similar increases across three D3 formulations, and a capsule-versus-oral-spray study was small with carryover limitations; a consensus source favors cholecalciferol for most contexts while reserving calcifediol and calcitriol for selected clinical situations.
    strength: moderate
    sourceKeys:
      - source_artifact:pmid-17456248
      - source_artifact:pmid-32365732
      - source_artifact:pmid-27724992
      - source_artifact:pmid-38676447
    caveats:
      - The extracted formulation evidence does not establish a best brand, excipient, meal timing, or delivery system.
      - Calcifediol, calcitriol, and active analogues are not interchangeable with routine D3 supplementation.
      - Oral spray evidence is small and not enough for a superiority claim.
  -
    claimId: dose-implementation-006-daily-frequency-versus-intermittent-regimens
    type: mixed_evidence
    text: Daily frequency should remain part of this protocol definition. Small adjacent trials suggest that equal cumulative daily, weekly, or monthly D3 can produce similar short-term 25(OH)D restoration, but kinetics differ; single, monthly, or annual high-dose bolus regimens are adjacent variants, and some high-dose intermittent trials reported fall or fracture safety signals. Do not collapse daily D3, weekly/monthly same-cumulative-dose dosing, and bolus megadose regimens into one claim.
    strength: moderate
    sourceKeys:
      - source_artifact:pmid-27718150
      - source_artifact:pmid-29882841
      - source_artifact:pmid-24424073
      - source_artifact:pmid-25271011
      - source_artifact:pmid-20460620
      - source_artifact:pmid-26747333
      - source_artifact:pmid-35504603
    caveats:
      - Schedule-comparison trials were small or adjacent and often focused on biochemical restoration.
      - High-dose bolus harm signals should not be used to imply that ordinary daily D3 is harmful, but they do argue against megadose substitution.
      - Clinical endpoints differed from biomarker endpoints.
  -
    claimId: dose-implementation-007-upper-dose-safety-boundary
    type: safety
    text: The adult 4000 IU/day or 100 micrograms/day level should be presented as an upper-intake safety boundary, not a routine target. Extracted upper-limit sources anchor 4000 IU/day as a tolerability ceiling, while a 3200-4000 IU/day RCT meta-analysis found increased hypercalcemia risk and a high-dose daily trial found lower volumetric BMD in 4000 IU/day and 10000 IU/day arms versus 400 IU/day. Higher daily doses belong in clinician-supervised or safety-boundary language.
    strength: high
    sourceKeys:
      - source_artifact:doi-10.17226-13050
      - source_artifact:doi-10.2903-j.efsa.2023.8145
      - source_artifact:nih-ods-vitamin-d-fact-sheet-2025-06-27
      - source_artifact:pmid-36853379
      - source_artifact:pmid-31454046
      - source_artifact:pmid-11157326
      - source_artifact:pmid-32857334
    caveats:
      - Upper-intake limits are not efficacy targets.
      - Some short monitored trials did not observe calcium-marker changes, but they were small or short.
      - Risk can differ with kidney disease, stone history, calcium supplements, medications, pregnancy, pediatrics, and other special contexts.
  -
    claimId: dose-implementation-008-biomarker-not-clinical-outcome-promise
    type: evidence_scope
    text: Dose implementation should promise only a trackable vitamin D status experiment, not disease prevention. Daily D3 biomarker increases coexist with null or mixed extracted clinical-outcome evidence for cancer, cardiovascular events, BMD, fractures, and fall/fracture outcomes depending on population, dose, interval, and cointerventions.
    strength: high
    sourceKeys:
      - source_artifact:pmid-30415629
      - source_artifact:pmid-31923341
      - source_artifact:pmid-35939577
      - source_artifact:pmid-35504603
      - source_artifact:pmid-20089776
      - source_artifact:pmid-31454046
    caveats:
      - This section is about dosing implementation; detailed clinical-outcome synthesis belongs elsewhere.
      - Some clinical-outcome reviews mix D3 alone, D3 plus calcium, different baseline statuses, and intermittent regimens.
      - Community outcomes should be labeled separately if users report subjective changes.
  -
    claimId: baseline-considerations-001-baseline-status-and-thresholds
    type: association_not_causation
    text: Baseline serum 25(OH)D should be treated as a major response modifier for daily D3: lower-baseline groups often show larger biomarker gains or different target-attainment behavior, but a fixed daily dose does not guarantee reaching any chosen threshold. Extracted evidence includes winter predictor analyses, baseline/BMI efficiency findings, low-baseline Chinese dose-response data, threshold-specific requirement models, and low-baseline systematic-review context.
    strength: high
    sourceKeys:
      - source_artifact:pmid-26037521
      - source_artifact:pmid-32365732
      - source_artifact:pmid-25694350
      - source_artifact:pmid-19064513
      - source_artifact:pmid-37764770
      - source_artifact:pmid-25835074
      - source_artifact:pmid-24993750
    caveats:
      - Thresholds differ across sources, including 30, 50, 75, and 80 nmol/L or ng/mL-based targets.
      - A larger 25(OH)D rise is a biomarker result, not proof of symptom or disease-outcome benefit.
      - These data do not provide a validated individual dose calculator.
  -
    claimId: baseline-considerations-002-season-latitude-sun-context
    type: design_guardrail
    text: Season, latitude, and sun exposure can change both starting status and the expected observable effect of daily D3. Several direct daily-D3 studies were winter studies, one winter placebo group declined while the active group rose, VITAL baseline 25(OH)D varied with latitude and season-related factors, and sunlight/UVB sources show that cutaneous vitamin D production depends strongly on season, latitude, exposure dose, and population context.
    strength: moderate
    sourceKeys:
      - source_artifact:pmid-12499343
      - source_artifact:pmid-19064513
      - source_artifact:pmid-26037521
      - source_artifact:pmid-31669447
      - source_artifact:pmid-2839537
      - source_artifact:pmid-20072137
      - source_artifact:pmid-21918215
    caveats:
      - UVB and sunlight studies are adjacent-mechanism context, not direct evidence that sun exposure should replace oral D3.
      - Real-life sun exposure depends on clothing, sunscreen, time of day, skin exposed, weather, behavior, and skin-safety constraints.
      - Latitude and season can confound a before/after self-experiment if the baseline and intervention periods occur in different sunlight conditions.
  -
    claimId: baseline-considerations-003-diet-and-fortified-foods-confounding
    type: design_guardrail
    text: Dietary vitamin D inputs, especially fortified foods, can raise or maintain serum 25(OH)D independently of a capsule/tablet supplement and should be logged or kept stable during the experiment. Fortified-food reviews and RCTs show 25(OH)D increases or prevention of winter decline, and one fortified-bread trial was extracted as comparable to an oral vitamin D supplement, but these are adjacent food-route data with substantial heterogeneity.
    strength: moderate
    sourceKeys:
      - source_artifact:pmid-19064512
      - source_artifact:pmid-22513988
      - source_artifact:pmid-34113994
      - source_artifact:pmid-37686773
      - source_artifact:pmid-23783292
      - source_artifact:pmid-27115063
    caveats:
      - Food-fortification evidence is adjacent to, not the same as, daily oral D3 supplementation.
      - Food vehicle, dose, adherence, latitude, baseline status, and season vary across studies.
      - The allowed extraction did not support a specific meal-timing or dietary-fat instruction for taking D3.
  -
    claimId: baseline-considerations-004-body-size-bmi-response-modifier
    type: association_not_causation
    text: Body weight, BMI, and adiposity should be treated as baseline context because extracted trials and syntheses repeatedly associate higher BMI or larger body size with lower baseline 25(OH)D or smaller serum-response increments. This supports biomarker-guided personalization and careful expectation setting, not a deterministic weight-based dosing rule for the page.
    strength: high
    sourceKeys:
      - source_artifact:pmid-22431675
      - source_artifact:pmid-32365732
      - source_artifact:pmid-36648947
      - source_artifact:pmid-31832878
      - source_artifact:pmid-26121531
      - source_artifact:pmid-33954783
    caveats:
      - BMI/body-size evidence is not a validated dosing formula.
      - Some subgroup studies include older adults, calcium co-supplementation, high-dose arms, or specific clinical contexts.
      - A page can mention response variability by body size but should avoid unsupervised dose escalation.
  -
    claimId: baseline-considerations-005-population-pigmentation-ethnicity-context
    type: mixed_evidence
    text: Race, ethnicity, skin-pigmentation, and related population markers should be recorded as context rather than converted into deterministic dose rules. Extracted sources show lower baseline 25(OH)D in some Black/African American or South Asian strata and smaller simulated-sunlight response in a South Asian UK cohort, while oral supplementation studies did not always find a clear race/ethnicity response difference; one meta-analysis reported ethnicity as a significant but highly heterogeneous response modifier.
    strength: moderate
    sourceKeys:
      - source_artifact:pmid-27194308
      - source_artifact:pmid-29498350
      - source_artifact:pmid-31669447
      - source_artifact:pmid-39432764
      - source_artifact:pmid-21918215
      - source_artifact:pmid-19812604
      - source_artifact:pmid-24256378
    caveats:
      - Race and ethnicity are broad proxies that can mix ancestry, pigmentation, diet, supplement use, clothing, latitude, body composition, and socioeconomic context.
      - Controlled UVB and real-life sunlight may behave differently; sunlight findings do not automatically apply to oral D3.
      - Binding-protein and genotype findings affect biomarker interpretation but are not direct dosing instructions.
  -
    claimId: baseline-considerations-006-clinical-outcomes-baseline-mismatch
    type: mixed_evidence
    text: For outcomes beyond serum 25(OH)D, baseline status should temper expectations: deficiency or very low baseline status may make benefit more plausible for some endpoints, but broad clinical-outcome evidence is mixed or null and not a basis for universal disease-prevention claims. Extracted sources preserve a limited deficient-subgroup muscle-strength signal, an earlier ARI IPD signal enriched in low-baseline/non-bolus contexts, a later ARI update without statistically significant overall protection or baseline-status modification, USPSTF evidence-review null findings for many outcomes in asymptomatic low-vitamin-D populations, and guideline cautions about universal prevention and testing claims.
    strength: moderate
    sourceKeys:
      - source_artifact:pmid-20924748
      - source_artifact:pmid-28202713
      - source_artifact:pmid-39993397
      - source_artifact:pmid-33847712
      - source_artifact:pmid-38828931
      - source_artifact:pmid-30285729
      - source_artifact:pmid-34815552
    caveats:
      - Most clinical-outcome syntheses aggregate heterogeneous doses, dosing intervals, populations, baseline statuses, and co-interventions.
      - This protocol section should keep serum 25(OH)D response separate from disease-prevention claims.
      - Guidelines and screening evidence apply to defined populations and do not replace care for symptomatic deficiency or established indications.
  -
    claimId: baseline-considerations-007-log-and-stabilize-modifiers
    type: design_guardrail
    text: The protocol page should ask users to log or keep stable the baseline modifiers most likely to confound interpretation: recent 25(OH)D if available, season, latitude/travel, sun or UV exposure, fortified-food or diet changes, body-weight/BMI context, dose, and adherence. These variables are repeatedly extracted as response modifiers or adjacent-route contributors, so they belong in experiment-design copy rather than as post-hoc explanations only.
    strength: moderate
    sourceKeys:
      - source_artifact:pmid-26037521
      - source_artifact:pmid-31669447
      - source_artifact:pmid-26121531
      - source_artifact:pmid-23783292
      - source_artifact:pmid-32365732
      - source_artifact:pmid-2839537
      - source_artifact:pmid-19064512
    caveats:
      - Logging a modifier does not establish causation for an individual result.
      - The page should avoid requiring routine blood testing for everyone; extracted guideline sources flag uncertainty around broad screening/testing claims.
      - This guardrail is for experiment interpretation, not medical diagnosis.
  -
    claimId: safety-monitoring-001-upper-limit-is-ceiling-not-target
    type: design_guardrail
    text: The protocol should treat 4,000 IU/day for adults as an upper-intake safety boundary, not as an efficacy target or default daily dose. IOM/NAM, EFSA, and NIH ODS all support upper-limit framing, and the upper-end daily-dose meta-analysis reported increased hypercalcemia risk at 3,200–4,000 IU/day.
    strength: high
    sourceKeys:
      - source_artifact:doi-10.17226-13050
      - source_artifact:doi-10.2903-j.efsa.2023.8145
      - source_artifact:nih-ods-vitamin-d-fact-sheet-2025-06-27
      - source_artifact:pmid-36853379
    caveats:
      - Age-specific and special-population limits differ outside the adult framing extracted here.
      - Upper-intake limits are safety ceilings, not treatment goals.
      - Upper-end daily-dose evidence should stay separate from ordinary maintenance-dose claims.
  -
    claimId: safety-monitoring-002-hypercalcemia-and-hypercalciuria-monitoring
    type: safety
    text: Hypercalcemia and hypercalciuria should be the main laboratory safety endpoints when daily D3 is high-dose, near the adult upper limit, combined with calcium, or used in a higher-risk person. Long-term vitamin D trials showed increased pooled risk for hypercalcemia and hypercalciuria, high-dose daily D3 showed dose-related calcium-lab events, while VITAL 2,000 IU/day and VITAL biomarker subsets did not show a major calcium safety signal.
    strength: moderate
    sourceKeys:
      - source_artifact:pmid-27604776
      - source_artifact:pmid-31746327
      - source_artifact:pmid-24937025
      - source_artifact:pmid-30415629
      - source_artifact:pmid-31669447
      - source_artifact:pmid-36648947
      - source_artifact:pmid-18541590
    caveats:
      - VITAL safety extraction did not repeat exact adverse-event counts.
      - Calcium co-supplementation prevents assigning all calcium-lab events to D3 alone.
      - No single extracted source defines a universal monitoring interval for all users.
  -
    claimId: safety-monitoring-003-kidney-stones-and-kidney-function-are-risk-context-not-universal-alarm
    type: mixed_evidence
    text: Kidney-stone and kidney-function language should be cautious and separated by context: pooled vitamin D supplementation evidence did not show a statistically significant kidney-stone increase, but vitamin D plus calcium increased kidney stones in WHI/USPSTF-reviewed evidence, stone-former evidence was small and short, and monitored D2d safety analyses tracked nephrolithiasis and low eGFR without a clear excess in the trial population.
    strength: moderate
    sourceKeys:
      - source_artifact:pmid-27604776
      - source_artifact:pmid-16481635
      - source_artifact:pmid-29677308
      - source_artifact:nih-ods-vitamin-d-fact-sheet-2025-06-27
      - source_artifact:pmid-29562593
      - source_artifact:pmid-27765695
      - source_artifact:pmid-35140313
      - source_artifact:pmid-33284677
      - source_artifact:pmid-27545576
    caveats:
      - Kidney-stone outcomes had fewer events or narrower endpoint-specific samples than broader safety analyses.
      - Calcium plus D3 should not be collapsed into D3-only evidence.
      - Stone-former monitoring advice comes from small clinical and review evidence, not a universal rule for all low-risk users.
      - D2d was screened and monitored and involved adults with prediabetes.
  -
    claimId: safety-monitoring-004-ckd-and-active-vitamin-d-are-clinician-supervised-boundaries
    type: safety
    text: Chronic kidney disease, CKD-MBD, and prescription active vitamin D or analogue use should route users to clinician-guided monitoring rather than ordinary self-directed daily D3 framing. Extracted CKD evidence involves different physiology, active vitamin D or analogues, calcium/phosphorus changes, and KDIGO-style supervised management; active vitamin D in non-dialysis CKD with secondary hyperparathyroidism was associated with increased hypercalcaemia in the extracted meta-analysis summary.
    strength: moderate
    sourceKeys:
      - source_artifact:pmcid-PMC8573010
      - source_artifact:pmid-19821446
      - source_artifact:pmid-30675420
      - source_artifact:pmid-19644521
      - source_artifact:pmid-37541585
      - source_artifact:pmid-35140313
    caveats:
      - Active vitamin D and analogues are not the same intervention as OTC cholecalciferol.
      - CKD evidence is special-population context, not a direct daily-D3 claim for healthy adults.
      - The extraction does not provide a single CKD monitoring schedule.
  -
    claimId: safety-monitoring-005-granulomatous-disease-screen-is-supported-but-sparsely-extracted
    type: evidence_scope
    text: Sarcoidosis or granulomatous-disease context should remain in the safety screen as a conservative hypercalcemia-risk guardrail, but the final page should not make detailed granulomatous-disease mechanism claims from this extraction. The VITAL safety extraction explicitly says the no-imbalance finding does not remove caution for sarcoidosis, and IOM/EFSA source-page drafts flag granulomatous disease as a population-mismatch context for upper-limit guidance.
    strength: low
    sourceKeys:
      - source_artifact:pmid-30415629
      - source_artifact:doi-10.17226-13050
      - source_artifact:doi-10.2903-j.efsa.2023.8145
      - source_artifact:pmid-30294301
    caveats:
      - The explicit sarcoidosis mention is a caveat in the VITAL extraction, not a dedicated granulomatous-disease trial.
      - The extracted record set supports only a conservative granulomatous-disease screen, not a detailed disease-mechanism claim.
      - Population-mismatch wording for granulomatous disease comes from source-page draft context rather than a separate atomic finding.
  -
    claimId: safety-monitoring-006-medication-and-supplement-interaction-screen-is-a-guardrail-not-a-drug-list
    type: evidence_scope
    text: The protocol should ask users to disclose medication and supplement co-use before starting or increasing D3, but this extraction supports only a broad interaction screen, not a specific drug-interaction list. Extracted records mention interacting medications as a safety generalizability caveat, diseases/medications as response modifiers, and drug interactions as a monitoring concern not resolved by aggregate serious-adverse-event findings.
    strength: low
    sourceKeys:
      - source_artifact:pmid-18541590
      - source_artifact:pmid-26121531
      - source_artifact:pmid-39993397
    caveats:
      - No extracted finding in this run supports a named medication-interaction table.
      - The page should say medication review is needed; it should not invent a specific interaction table from this run.
      - Supplement stacking, calcium co-use, calcitriol/calcifediol, and high-dose products are better supported than specific drug names in this extraction.
  -
    claimId: safety-monitoring-007-toxicity-and-product-error-monitoring
    type: safety
    text: Vitamin D toxicity language should emphasize excess cumulative exposure, aggressive correction, supplement stacking, and product or prescribing errors rather than implying common toxicity at ordinary labeled doses. Extracted toxicity sources document hypercalcemia-focused management and cases or recalls involving manufacturing, labeling, compounding, or overzealous correction contexts.
    strength: moderate
    sourceKeys:
      - source_artifact:nih-ods-vitamin-d-fact-sheet-2025-06-27
      - source_artifact:fda-glades-vitamin-d3-recall-2015-11-25
      - source_artifact:pmid-21917864
      - source_artifact:pmid-22043417
      - source_artifact:pmid-26053339
      - source_artifact:pmid-32491799
    caveats:
      - Case reports, case series, and recall notices do not provide incidence estimates for normal-dose users.
      - Product-error evidence is safety-boundary evidence only.
      - The extraction does not provide a validated symptom checklist or lab threshold for emergency triage.
  -
    claimId: safety-monitoring-008-risk-based-monitoring-is-not-routine-population-screening
    type: design_guardrail
    text: The protocol should distinguish risk-based safety monitoring from routine population screening or target-chasing. The 2024 Endocrine Society guideline cautions against routine 25(OH)D testing in prevention populations and notes threshold uncertainty, while USPSTF found insufficient direct evidence for screening asymptomatic community-dwelling adults; those screening cautions do not remove the need for calcium, urine-calcium, kidney-stone, or kidney-function monitoring in high-risk or high-dose contexts.
    strength: high
    sourceKeys:
      - source_artifact:pmid-38828931
      - source_artifact:pmid-33847711
      - source_artifact:pmid-33847712
      - source_artifact:pmid-29562593
      - source_artifact:pmid-35140313
    caveats:
      - USPSTF screening guidance applies to asymptomatic, community-dwelling, nonpregnant adults without conditions requiring vitamin D treatment.
      - Testing guidance does not replace clinical evaluation for symptoms, known deficiency, CKD, stones, hypercalcemia risk, or supervised deficiency treatment.
      - The extraction does not define a single lab-testing schedule for the protocol.
  -
    claimId: outcome-metrics-001-25ohd-primary-lab-outcome
    type: intervention_result
    text: Serum or plasma 25(OH)D should be the primary outcome metric for Daily Vitamin D3 Supplementation because direct daily-D3 trials and a healthy-adult meta-analysis repeatedly show measurable 25(OH)D increases over weeks to months. The page should still avoid turning a biomarker rise into a claim of symptom, fracture, infection, or mood benefit, and should acknowledge debated thresholds and assay-standardization limits.
    strength: high
    sourceKeys:
      - source_artifact:pmid-12499343
      - source_artifact:pmid-19064513
      - source_artifact:pmid-26037521
      - source_artifact:pmid-32365732
      - source_artifact:pmid-31669447
      - source_artifact:pmid-37764770
    caveats:
      - 25(OH)D is a biochemical exposure/status metric, not proof of downstream clinical benefit.
      - Threshold targets differ across sources and professional frameworks; threshold/testing sources are context-only rather than direct protocol evidence.
      - Assay standardization and unit differences can complicate comparison across labs.
  -
    claimId: outcome-metrics-002-25ohd-follow-up-window-and-response-variability
    type: design_guardrail
    text: The protocol should treat 25(OH)D follow-up as a weeks-to-months measure, not a daily symptom-like readout. Extracted daily-D3 studies measured meaningful changes after about 4 weeks, 8-12 weeks, 16 weeks, 20-22 weeks, 2 months, 1 year, or longer, and response varied with baseline status, BMI/body weight, age, and lifestyle factors.
    strength: high
    sourceKeys:
      - source_artifact:pmid-17456248
      - source_artifact:pmid-26037521
      - source_artifact:pmid-25694350
      - source_artifact:pmid-12499343
      - source_artifact:pmid-19064513
      - source_artifact:pmid-32365732
      - source_artifact:pmid-27683872
      - source_artifact:pmid-36648947
    caveats:
      - The extracted studies do not define one universal retest interval for every user.
      - Season, sun exposure, diet/fortification, adherence, and dose changes can confound before-after interpretation.
      - Response predictors are not validated as an individual dose calculator.
  -
    claimId: outcome-metrics-003-bmd-bone-turnover-and-fracture-are-long-horizon-not-short-run-metrics
    type: mixed_evidence
    text: BMD, bone-turnover markers, PTH, and fractures should be framed as long-horizon clinical or research outcomes rather than short-run self-experiment metrics. Direct and broad evidence includes null VITAL BMD and fracture findings, null or mixed bone-turnover/PTH findings, broad musculoskeletal reviews with null or clinically small effects, and one dose/interval meta-analysis suggesting possible benefit for daily 800-1000 IU that should be kept separate from a direct protocol claim.
    strength: high
    sourceKeys:
      - source_artifact:pmid-20089776
      - source_artifact:pmid-22695105
      - source_artifact:pmid-31923341
      - source_artifact:pmid-35939577
      - source_artifact:pmid-24119980
      - source_artifact:pmid-30293909
      - source_artifact:pmid-29279934
      - source_artifact:pmid-34687206
      - source_artifact:pmid-35504603
    caveats:
      - BMD and fracture outcomes need long follow-up and are not practical feedback signals for a short personal run.
      - Calcium co-supplementation, institutionalized populations, osteoporosis treatment, and deficiency treatment are different evidence contexts.
      - A possible pooled benefit for a dose band should not be phrased as guaranteed benefit for daily D3 monotherapy.
  -
    claimId: outcome-metrics-004-muscle-function-and-falls-are-exploratory-user-relevant-metrics
    type: mixed_evidence
    text: Manual muscle-function tests and falls logs can be user-relevant exploratory measures, especially for older or fall-risk users, but they should not be presented as expected improvements. Direct VITAL falls evidence was null using annual self-report and doctor/hospital-visit fall outcomes; a postmenopausal insufficiency trial found no differences in timed-up-and-go, sit-to-stand, falls, or function; an older-adult muscle trial found no improvements in leg power, strength, SPPB, timed-up-and-go, gait, or postural sway; systematic reviews are mixed and sometimes limited to deficient subgroups.
    strength: moderate
    sourceKeys:
      - source_artifact:pmid-32492153
      - source_artifact:pmid-26237520
      - source_artifact:pmid-37084814
      - source_artifact:pmid-33170239
      - source_artifact:pmid-35136915
      - source_artifact:pmid-20924748
      - source_artifact:pmid-25033068
      - source_artifact:pmid-33284677
    caveats:
      - Falls are infrequent and often self-reported, so a single-user run is underpowered for prevention claims.
      - Older, fall-risk, low-functioning, or deficient populations may not generalize to low-risk users.
      - High-dose or dose-finding fall trials are safety/evidence-boundary context, not ordinary-dose efficacy proof.
  -
    claimId: outcome-metrics-005-immune-and-respiratory-measures-are-mixed-and-self-report-heavy
    type: mixed_evidence
    text: Immune and respiratory outcomes should be optional exploratory measures, not a promised benefit. Direct daily-D3 URI trials and VITAL URI analyses were null or uncertain despite biomarker increases; cytokine and immune-function studies were null or exploratory; the 2017 individual-participant-data meta-analysis reported reduced acute respiratory infection risk, while a later aggregate-data meta-analysis did not find a statistically significant overall effect.
    strength: moderate
    sourceKeys:
      - source_artifact:pmid-19296870
      - source_artifact:pmid-24014734
      - source_artifact:pmid-38113446
      - source_artifact:pmid-21270359
      - source_artifact:pmid-24327720
      - source_artifact:pmid-34262557
      - source_artifact:pmid-36386950
      - source_artifact:pmid-28202713
      - source_artifact:pmid-39993397
      - source_artifact:pmid-33170239
    caveats:
      - Many respiratory endpoints are self-reported symptoms, diaries, or surveys without viral confirmation.
      - Biomarker response and cytokine changes do not establish fewer infections.
      - Meta-analyses differ by included trials, dosing schedules, baseline status, and analytic approach.
  -
    claimId: outcome-metrics-006-mood-and-fatigue-should-not-be-evidence-backed-primary-endpoints
    type: evidence_scope
    text: Mood, depressive symptoms, well-being, and fatigue should not be treated as evidence-backed primary endpoints for this protocol from the current extraction. The available mood-related extraction was adjacent UVB-versus-weekly-oral evidence in frail nursing-home residents with dementia, and the USPSTF evidence report found no depression effect among screen-relevant asymptomatic low-vitamin-D treatment studies while noting uncertainty for physical functioning and infection; no direct daily-D3 fatigue finding was extracted.
    strength: low
    sourceKeys:
      - source_artifact:doi-10.3390-ijerph17051684
      - source_artifact:pmid-33847712
    caveats:
      - Mood/fatigue logs may be retained as community or personal exploratory outcomes, but should be labeled exploratory.
      - The extracted dementia/UVB source is population- and route-mismatched for daily D3.
      - Fatigue-specific direct D3 evidence was not present in the allowed extraction artifacts.
  -
    claimId: outcome-metrics-007-use-a-measurement-hierarchy-and-label-self-report-limits
    type: design_guardrail
    text: The page should use a measurement hierarchy: objective lab 25(OH)D as the primary measurable response; optional safety or clinical labs only when indicated; manual tests such as grip, sit-to-stand, timed-up-and-go, SPPB, gait, or BMD testing only when they match the user's context; and self-reported falls, URIs, mood, or fatigue as exploratory logs. Extracted falls and URI studies commonly used annual self-report, daily symptom diaries, semiannual surveys, or survey/diary subsets, while fracture outcomes require long follow-up or linked/trial-level event data.
    strength: moderate
    sourceKeys:
      - source_artifact:pmid-32492153
      - source_artifact:pmid-24014734
      - source_artifact:pmid-38113446
      - source_artifact:pmid-34337905
      - source_artifact:pmid-37011645
      - source_artifact:pmid-35939577
      - source_artifact:pmid-31923341
    caveats:
      - Self-report is vulnerable to recall, expectation, season, and healthcare-access confounding.
      - Manual tests require standardized conditions and may still be underpowered for a short supplement run.
      - Fractures and BMD are not appropriate short-run personal feedback metrics.
researchLandscape:
  bottomLine: Daily oral D3 has direct evidence for raising serum 25(OH)D over weeks, while downstream clinical outcomes are mixed or population-specific and safety boundaries should dominate dosing decisions.
  confidenceLabel: moderate
  primaryClaim: The protocol is best justified as a vitamin D status / 25(OH)D biomarker experiment.
  mainCaveat: Do not present daily D3 as a guaranteed symptom, fracture, infection, mood, fatigue, cardiovascular, or longevity intervention.
  groups:

    -
      id: dose-implementation-001-direct-daily-d3-dose-response
      label: Direct Daily D3 Dose Response
      stance: supports
      summary: Direct daily oral cholecalciferol evidence supports a dose-related increase in serum 25(OH)D over weeks. Extracted direct trials and syntheses include winter dose-response arms, 400-2000 IU/day arms, 800 IU/day and 1000 IU/day trials, and a European healthy-adult meta-analysis estimating a pooled serum 25(OH)D increase versus placebo. This supports daily D3 as a biomarker protocol, not as proof of broad clinical benefit.
      sourceKeys:
        - source_artifact:pmid-12499343
        - source_artifact:pmid-19064513
        - source_artifact:pmid-20089776
        - source_artifact:pmid-25694350
        - source_artifact:pmid-26037521
        - source_artifact:pmid-32365732
        - source_artifact:pmid-37764770
    -
      id: dose-implementation-002-800-to-1000-iu-range-with-target-caveats
      label: 800 To 1000 Iu Range With Target Caveats
      stance: mixed
      summary: For protocol implementation copy, 800-1000 IU/day can be presented as a common evidence-supported adult starting or maintenance range, but not as a guaranteed target-achieving dose. One postmenopausal-women trial found 800 IU/day raised 25(OH)D above 50 nmol/L in 97.5% of participants, an 800 IU/day winter RCT reported 94% reaching at least 50 nmol/L by study end, and a European meta-analysis modeled about 1000 IU/day to bring 95% of healthy adults to at least 50 nmol/L; however, a healthy Chinese low-baseline trial found that even 2000 IU/day did not bring 97.5% of participants to at least 50 nmol/L by 16 weeks.
      sourceKeys:
        - source_artifact:pmid-19064513
        - source_artifact:pmid-22431675
        - source_artifact:pmid-25694350
        - source_artifact:pmid-26037521
        - source_artifact:pmid-37764770
    -
      id: dose-implementation-003-response-modifiers-and-individualization
      label: Response Modifiers And Individualization
      stance: context_only
      summary: Dose response should be described as individualized rather than one-size-fits-all: extracted evidence links response variability to baseline 25(OH)D, BMI/body weight or obesity, age, ethnicity or race-related strata, season/sun context, and chosen target threshold. Higher-target or higher-BMI contexts sometimes used or modeled higher daily doses, but those data should prompt biomarker-guided personalization rather than unsupervised dose escalation.
      sourceKeys:
        - source_artifact:pmid-18541590
        - source_artifact:pmid-22431675
        - source_artifact:pmid-26037521
        - source_artifact:pmid-27194308
        - source_artifact:pmid-31832878
        - source_artifact:pmid-32365732
        - source_artifact:pmid-33954783
        - source_artifact:pmid-36648947
        - source_artifact:pmid-39432764
    -
      id: dose-implementation-004-wash-in-and-evaluation-window
      label: Wash In And Evaluation Window
      stance: context_only
      summary: Daily D3 response should be evaluated over weeks, not days. Extracted trials observed meaningful 25(OH)D changes at 4 weeks, 8-12 weeks, 16 weeks, and approximately 20-22 weeks; therefore a protocol page can reasonably tell users to keep dosing consistent and avoid judging the dose from short-term symptoms or a few days of use.
      sourceKeys:
        - source_artifact:pmid-12499343
        - source_artifact:pmid-17456248
        - source_artifact:pmid-19064513
        - source_artifact:pmid-25694350
        - source_artifact:pmid-26037521
        - source_artifact:pmid-31669447
    -
      id: dose-implementation-005-default-formulation-oral-cholecalciferol
      label: Default Formulation Oral Cholecalciferol
      stance: context_only
      summary: The protocol should default to oral cholecalciferol/D3 and avoid claiming superiority for a specific consumer form. A 10 µg/day trial found no clear advantage between multivitamin tablets and fish-oil capsules, a 1000 IU/day study found similar increases across three D3 formulations, and a capsule-versus-oral-spray study was small with carryover limitations; a consensus source favors cholecalciferol for most contexts while reserving calcifediol and calcitriol for selected clinical situations.
      sourceKeys:
        - source_artifact:pmid-17456248
        - source_artifact:pmid-27724992
        - source_artifact:pmid-32365732
        - source_artifact:pmid-38676447
    -
      id: dose-implementation-006-daily-frequency-versus-intermittent-regimens
      label: Daily Frequency Versus Intermittent Regimens
      stance: mixed
      summary: Daily frequency should remain part of this protocol definition. Small adjacent trials suggest that equal cumulative daily, weekly, or monthly D3 can produce similar short-term 25(OH)D restoration, but kinetics differ; single, monthly, or annual high-dose bolus regimens are adjacent variants, and some high-dose intermittent trials reported fall or fracture safety signals. Do not collapse daily D3, weekly/monthly same-cumulative-dose dosing, and bolus megadose regimens into one claim.
      sourceKeys:
        - source_artifact:pmid-20460620
        - source_artifact:pmid-24424073
        - source_artifact:pmid-25271011
        - source_artifact:pmid-26747333
        - source_artifact:pmid-27718150
        - source_artifact:pmid-29882841
        - source_artifact:pmid-35504603
    -
      id: dose-implementation-007-upper-dose-safety-boundary
      label: Upper Dose Safety Boundary
      stance: safety_boundary
      summary: The adult 4000 IU/day or 100 micrograms/day level should be presented as an upper-intake safety boundary, not a routine target. Extracted upper-limit sources anchor 4000 IU/day as a tolerability ceiling, while a 3200-4000 IU/day RCT meta-analysis found increased hypercalcemia risk and a high-dose daily trial found lower volumetric BMD in 4000 IU/day and 10000 IU/day arms versus 400 IU/day. Higher daily doses belong in clinician-supervised or safety-boundary language.
      sourceKeys:
        - source_artifact:doi-10.17226-13050
        - source_artifact:doi-10.2903-j.efsa.2023.8145
        - source_artifact:nih-ods-vitamin-d-fact-sheet-2025-06-27
        - source_artifact:pmid-11157326
        - source_artifact:pmid-31454046
        - source_artifact:pmid-32857334
        - source_artifact:pmid-36853379
    -
      id: dose-implementation-008-biomarker-not-clinical-outcome-promise
      label: Biomarker Not Clinical Outcome Promise
      stance: mixed
      summary: Dose implementation should promise only a trackable vitamin D status experiment, not disease prevention. Daily D3 biomarker increases coexist with null or mixed extracted clinical-outcome evidence for cancer, cardiovascular events, BMD, fractures, and fall/fracture outcomes depending on population, dose, interval, and cointerventions.
      sourceKeys:
        - source_artifact:pmid-20089776
        - source_artifact:pmid-30415629
        - source_artifact:pmid-31454046
        - source_artifact:pmid-31923341
        - source_artifact:pmid-35504603
        - source_artifact:pmid-35939577
    -
      id: baseline-considerations-001-baseline-status-and-thresholds
      label: Baseline Status And Thresholds
      stance: context_only
      summary: Baseline serum 25(OH)D should be treated as a major response modifier for daily D3: lower-baseline groups often show larger biomarker gains or different target-attainment behavior, but a fixed daily dose does not guarantee reaching any chosen threshold. Extracted evidence includes winter predictor analyses, baseline/BMI efficiency findings, low-baseline Chinese dose-response data, threshold-specific requirement models, and low-baseline systematic-review context.
      sourceKeys:
        - source_artifact:pmid-19064513
        - source_artifact:pmid-24993750
        - source_artifact:pmid-25694350
        - source_artifact:pmid-25835074
        - source_artifact:pmid-26037521
        - source_artifact:pmid-32365732
        - source_artifact:pmid-37764770
    -
      id: baseline-considerations-002-season-latitude-sun-context
      label: Season Latitude Sun Context
      stance: context_only
      summary: Season, latitude, and sun exposure can change both starting status and the expected observable effect of daily D3. Several direct daily-D3 studies were winter studies, one winter placebo group declined while the active group rose, VITAL baseline 25(OH)D varied with latitude and season-related factors, and sunlight/UVB sources show that cutaneous vitamin D production depends strongly on season, latitude, exposure dose, and population context.
      sourceKeys:
        - source_artifact:pmid-12499343
        - source_artifact:pmid-19064513
        - source_artifact:pmid-20072137
        - source_artifact:pmid-21918215
        - source_artifact:pmid-26037521
        - source_artifact:pmid-2839537
        - source_artifact:pmid-31669447
    -
      id: baseline-considerations-003-diet-and-fortified-foods-confounding
      label: Diet And Fortified Foods Confounding
      stance: context_only
      summary: Dietary vitamin D inputs, especially fortified foods, can raise or maintain serum 25(OH)D independently of a capsule/tablet supplement and should be logged or kept stable during the experiment. Fortified-food reviews and RCTs show 25(OH)D increases or prevention of winter decline, and one fortified-bread trial was extracted as comparable to an oral vitamin D supplement, but these are adjacent food-route data with substantial heterogeneity.
      sourceKeys:
        - source_artifact:pmid-19064512
        - source_artifact:pmid-22513988
        - source_artifact:pmid-23783292
        - source_artifact:pmid-27115063
        - source_artifact:pmid-34113994
        - source_artifact:pmid-37686773
    -
      id: baseline-considerations-004-body-size-bmi-response-modifier
      label: Body Size Bmi Response Modifier
      stance: context_only
      summary: Body weight, BMI, and adiposity should be treated as baseline context because extracted trials and syntheses repeatedly associate higher BMI or larger body size with lower baseline 25(OH)D or smaller serum-response increments. This supports biomarker-guided personalization and careful expectation setting, not a deterministic weight-based dosing rule for the page.
      sourceKeys:
        - source_artifact:pmid-22431675
        - source_artifact:pmid-26121531
        - source_artifact:pmid-31832878
        - source_artifact:pmid-32365732
        - source_artifact:pmid-33954783
        - source_artifact:pmid-36648947
    -
      id: baseline-considerations-005-population-pigmentation-ethnicity-context
      label: Population Pigmentation Ethnicity Context
      stance: mixed
      summary: Race, ethnicity, skin-pigmentation, and related population markers should be recorded as context rather than converted into deterministic dose rules. Extracted sources show lower baseline 25(OH)D in some Black/African American or South Asian strata and smaller simulated-sunlight response in a South Asian UK cohort, while oral supplementation studies did not always find a clear race/ethnicity response difference; one meta-analysis reported ethnicity as a significant but highly heterogeneous response modifier.
      sourceKeys:
        - source_artifact:pmid-19812604
        - source_artifact:pmid-21918215
        - source_artifact:pmid-24256378
        - source_artifact:pmid-27194308
        - source_artifact:pmid-29498350
        - source_artifact:pmid-31669447
        - source_artifact:pmid-39432764
    -
      id: baseline-considerations-006-clinical-outcomes-baseline-mismatch
      label: Clinical Outcomes Baseline Mismatch
      stance: mixed
      summary: For outcomes beyond serum 25(OH)D, baseline status should temper expectations: deficiency or very low baseline status may make benefit more plausible for some endpoints, but broad clinical-outcome evidence is mixed or null and not a basis for universal disease-prevention claims. Extracted sources preserve a limited deficient-subgroup muscle-strength signal, an earlier ARI IPD signal enriched in low-baseline/non-bolus contexts, a later ARI update without statistically significant overall protection or baseline-status modification, USPSTF evidence-review null findings for many outcomes in asymptomatic low-vitamin-D populations, and guideline cautions about universal prevention and testing claims.
      sourceKeys:
        - source_artifact:pmid-20924748
        - source_artifact:pmid-28202713
        - source_artifact:pmid-30285729
        - source_artifact:pmid-33847712
        - source_artifact:pmid-34815552
        - source_artifact:pmid-38828931
        - source_artifact:pmid-39993397
    -
      id: baseline-considerations-007-log-and-stabilize-modifiers
      label: Log And Stabilize Modifiers
      stance: context_only
      summary: The protocol page should ask users to log or keep stable the baseline modifiers most likely to confound interpretation: recent 25(OH)D if available, season, latitude/travel, sun or UV exposure, fortified-food or diet changes, body-weight/BMI context, dose, and adherence. These variables are repeatedly extracted as response modifiers or adjacent-route contributors, so they belong in experiment-design copy rather than as post-hoc explanations only.
      sourceKeys:
        - source_artifact:pmid-19064512
        - source_artifact:pmid-23783292
        - source_artifact:pmid-26037521
        - source_artifact:pmid-26121531
        - source_artifact:pmid-2839537
        - source_artifact:pmid-31669447
        - source_artifact:pmid-32365732
    -
      id: safety-monitoring-001-upper-limit-is-ceiling-not-target
      label: Upper Limit Is Ceiling Not Target
      stance: safety_boundary
      summary: The protocol should treat 4,000 IU/day for adults as an upper-intake safety boundary, not as an efficacy target or default daily dose. IOM/NAM, EFSA, and NIH ODS all support upper-limit framing, and the upper-end daily-dose meta-analysis reported increased hypercalcemia risk at 3,200–4,000 IU/day.
      sourceKeys:
        - source_artifact:doi-10.17226-13050
        - source_artifact:doi-10.2903-j.efsa.2023.8145
        - source_artifact:nih-ods-vitamin-d-fact-sheet-2025-06-27
        - source_artifact:pmid-36853379
    -
      id: safety-monitoring-002-hypercalcemia-and-hypercalciuria-monitoring
      label: Hypercalcemia And Hypercalciuria Monitoring
      stance: safety_boundary
      summary: Hypercalcemia and hypercalciuria should be the main laboratory safety endpoints when daily D3 is high-dose, near the adult upper limit, combined with calcium, or used in a higher-risk person. Long-term vitamin D trials showed increased pooled risk for hypercalcemia and hypercalciuria, high-dose daily D3 showed dose-related calcium-lab events, while VITAL 2,000 IU/day and VITAL biomarker subsets did not show a major calcium safety signal.
      sourceKeys:
        - source_artifact:pmid-18541590
        - source_artifact:pmid-24937025
        - source_artifact:pmid-27604776
        - source_artifact:pmid-30415629
        - source_artifact:pmid-31669447
        - source_artifact:pmid-31746327
        - source_artifact:pmid-36648947
    -
      id: safety-monitoring-003-kidney-stones-and-kidney-function-are-risk-context-not-universal-alarm
      label: Kidney Stones And Kidney Function Are Risk Context Not Universal Alarm
      stance: mixed
      summary: Kidney-stone and kidney-function language should be cautious and separated by context: pooled vitamin D supplementation evidence did not show a statistically significant kidney-stone increase, but vitamin D plus calcium increased kidney stones in WHI/USPSTF-reviewed evidence, stone-former evidence was small and short, and monitored D2d safety analyses tracked nephrolithiasis and low eGFR without a clear excess in the trial population.
      sourceKeys:
        - source_artifact:nih-ods-vitamin-d-fact-sheet-2025-06-27
        - source_artifact:pmid-16481635
        - source_artifact:pmid-27545576
        - source_artifact:pmid-27604776
        - source_artifact:pmid-27765695
        - source_artifact:pmid-29562593
        - source_artifact:pmid-29677308
        - source_artifact:pmid-33284677
        - source_artifact:pmid-35140313
    -
      id: safety-monitoring-004-ckd-and-active-vitamin-d-are-clinician-supervised-boundaries
      label: Ckd And Active Vitamin D Are Clinician Supervised Boundaries
      stance: safety_boundary
      summary: Chronic kidney disease, CKD-MBD, and prescription active vitamin D or analogue use should route users to clinician-guided monitoring rather than ordinary self-directed daily D3 framing. Extracted CKD evidence involves different physiology, active vitamin D or analogues, calcium/phosphorus changes, and KDIGO-style supervised management; active vitamin D in non-dialysis CKD with secondary hyperparathyroidism was associated with increased hypercalcaemia in the extracted meta-analysis summary.
      sourceKeys:
        - source_artifact:pmcid-PMC8573010
        - source_artifact:pmid-19644521
        - source_artifact:pmid-19821446
        - source_artifact:pmid-30675420
        - source_artifact:pmid-35140313
        - source_artifact:pmid-37541585
    -
      id: safety-monitoring-005-granulomatous-disease-screen-is-supported-but-sparsely-extracted
      label: Granulomatous Disease Screen Is Supported But Sparsely Extracted
      stance: safety_boundary
      summary: Sarcoidosis or granulomatous-disease context should remain in the safety screen as a conservative hypercalcemia-risk guardrail, but the final page should not make detailed granulomatous-disease mechanism claims from this extraction. The VITAL safety extraction explicitly says the no-imbalance finding does not remove caution for sarcoidosis, and IOM/EFSA source-page drafts flag granulomatous disease as a population-mismatch context for upper-limit guidance.
      sourceKeys:
        - source_artifact:doi-10.17226-13050
        - source_artifact:doi-10.2903-j.efsa.2023.8145
        - source_artifact:pmid-30294301
        - source_artifact:pmid-30415629
    -
      id: safety-monitoring-006-medication-and-supplement-interaction-screen-is-a-guardrail-not-a-drug-list
      label: Medication And Supplement Interaction Screen Is A Guardrail Not A Drug List
      stance: safety_boundary
      summary: The protocol should ask users to disclose medication and supplement co-use before starting or increasing D3, but this extraction supports only a broad interaction screen, not a specific drug-interaction list. Extracted records mention interacting medications as a safety generalizability caveat, diseases/medications as response modifiers, and drug interactions as a monitoring concern not resolved by aggregate serious-adverse-event findings.
      sourceKeys:
        - source_artifact:pmid-18541590
        - source_artifact:pmid-26121531
        - source_artifact:pmid-39993397
    -
      id: safety-monitoring-007-toxicity-and-product-error-monitoring
      label: Toxicity And Product Error Monitoring
      stance: safety_boundary
      summary: Vitamin D toxicity language should emphasize excess cumulative exposure, aggressive correction, supplement stacking, and product or prescribing errors rather than implying common toxicity at ordinary labeled doses. Extracted toxicity sources document hypercalcemia-focused management and cases or recalls involving manufacturing, labeling, compounding, or overzealous correction contexts.
      sourceKeys:
        - source_artifact:fda-glades-vitamin-d3-recall-2015-11-25
        - source_artifact:nih-ods-vitamin-d-fact-sheet-2025-06-27
        - source_artifact:pmid-21917864
        - source_artifact:pmid-22043417
        - source_artifact:pmid-26053339
        - source_artifact:pmid-32491799
    -
      id: safety-monitoring-008-risk-based-monitoring-is-not-routine-population-screening
      label: Risk Based Monitoring Is Not Routine Population Screening
      stance: safety_boundary
      summary: The protocol should distinguish risk-based safety monitoring from routine population screening or target-chasing. The 2024 Endocrine Society guideline cautions against routine 25(OH)D testing in prevention populations and notes threshold uncertainty, while USPSTF found insufficient direct evidence for screening asymptomatic community-dwelling adults; those screening cautions do not remove the need for calcium, urine-calcium, kidney-stone, or kidney-function monitoring in high-risk or high-dose contexts.
      sourceKeys:
        - source_artifact:pmid-29562593
        - source_artifact:pmid-33847711
        - source_artifact:pmid-33847712
        - source_artifact:pmid-35140313
        - source_artifact:pmid-38828931
    -
      id: outcome-metrics-001-25ohd-primary-lab-outcome
      label: 25ohd Primary Lab Outcome
      stance: mixed
      summary: Serum or plasma 25(OH)D should be the primary outcome metric for Daily Vitamin D3 Supplementation because direct daily-D3 trials and a healthy-adult meta-analysis repeatedly show measurable 25(OH)D increases over weeks to months. The page should still avoid turning a biomarker rise into a claim of symptom, fracture, infection, or mood benefit, and should acknowledge debated thresholds and assay-standardization limits.
      sourceKeys:
        - source_artifact:pmid-12499343
        - source_artifact:pmid-19064513
        - source_artifact:pmid-26037521
        - source_artifact:pmid-31669447
        - source_artifact:pmid-32365732
        - source_artifact:pmid-37764770
        - source_artifact:pmid-38676447
        - source_artifact:pmid-38828931
    -
      id: outcome-metrics-002-25ohd-follow-up-window-and-response-variability
      label: 25ohd Follow Up Window And Response Variability
      stance: context_only
      summary: The protocol should treat 25(OH)D follow-up as a weeks-to-months measure, not a daily symptom-like readout. Extracted daily-D3 studies measured meaningful changes after about 4 weeks, 8-12 weeks, 16 weeks, 20-22 weeks, 2 months, 1 year, or longer, and response varied with baseline status, BMI/body weight, age, and lifestyle factors.
      sourceKeys:
        - source_artifact:pmid-12499343
        - source_artifact:pmid-17456248
        - source_artifact:pmid-19064513
        - source_artifact:pmid-25694350
        - source_artifact:pmid-26037521
        - source_artifact:pmid-27683872
        - source_artifact:pmid-32365732
        - source_artifact:pmid-36648947
    -
      id: outcome-metrics-003-bmd-bone-turnover-and-fracture-are-long-horizon-not-short-run-metrics
      label: Bmd Bone Turnover And Fracture Are Long Horizon Not Short Run Metrics
      stance: mixed
      summary: BMD, bone-turnover markers, PTH, and fractures should be framed as long-horizon clinical or research outcomes rather than short-run self-experiment metrics. Direct and broad evidence includes null VITAL BMD and fracture findings, null or mixed bone-turnover/PTH findings, broad musculoskeletal reviews with null or clinically small effects, and one dose/interval meta-analysis suggesting possible benefit for daily 800-1000 IU that should be kept separate from a direct protocol claim.
      sourceKeys:
        - source_artifact:pmid-20089776
        - source_artifact:pmid-22695105
        - source_artifact:pmid-24119980
        - source_artifact:pmid-29279934
        - source_artifact:pmid-30293909
        - source_artifact:pmid-31923341
        - source_artifact:pmid-34687206
        - source_artifact:pmid-35504603
        - source_artifact:pmid-35939577
    -
      id: outcome-metrics-004-muscle-function-and-falls-are-exploratory-user-relevant-metrics
      label: Muscle Function And Falls Are Exploratory User Relevant Metrics
      stance: mixed
      summary: Manual muscle-function tests and falls logs can be user-relevant exploratory measures, especially for older or fall-risk users, but they should not be presented as expected improvements. Direct VITAL falls evidence was null using annual self-report and doctor/hospital-visit fall outcomes; a postmenopausal insufficiency trial found no differences in timed-up-and-go, sit-to-stand, falls, or function; an older-adult muscle trial found no improvements in leg power, strength, SPPB, timed-up-and-go, gait, or postural sway; systematic reviews are mixed and sometimes limited to deficient subgroups.
      sourceKeys:
        - source_artifact:pmid-20924748
        - source_artifact:pmid-25033068
        - source_artifact:pmid-26237520
        - source_artifact:pmid-32492153
        - source_artifact:pmid-33170239
        - source_artifact:pmid-33284677
        - source_artifact:pmid-35136915
        - source_artifact:pmid-37084814
    -
      id: outcome-metrics-005-immune-and-respiratory-measures-are-mixed-and-self-report-heavy
      label: Immune And Respiratory Measures Are Mixed And Self Report Heavy
      stance: mixed
      summary: Immune and respiratory outcomes should be optional exploratory measures, not a promised benefit. Direct daily-D3 URI trials and VITAL URI analyses were null or uncertain despite biomarker increases; cytokine and immune-function studies were null or exploratory; the 2017 individual-participant-data meta-analysis reported reduced acute respiratory infection risk, while a later aggregate-data meta-analysis did not find a statistically significant overall effect.
      sourceKeys:
        - source_artifact:pmid-19296870
        - source_artifact:pmid-21270359
        - source_artifact:pmid-24014734
        - source_artifact:pmid-24327720
        - source_artifact:pmid-28202713
        - source_artifact:pmid-33170239
        - source_artifact:pmid-34262557
        - source_artifact:pmid-36386950
        - source_artifact:pmid-38113446
        - source_artifact:pmid-39993397
    -
      id: outcome-metrics-006-mood-and-fatigue-should-not-be-evidence-backed-primary-endpoints
      label: Mood And Fatigue Should Not Be Evidence Backed Primary Endpoints
      stance: context_only
      summary: Mood, depressive symptoms, well-being, and fatigue should not be treated as evidence-backed primary endpoints for this protocol from the current extraction. The available mood-related extraction was adjacent UVB-versus-weekly-oral evidence in frail nursing-home residents with dementia, and the USPSTF evidence report found no depression effect among screen-relevant asymptomatic low-vitamin-D treatment studies while noting uncertainty for physical functioning and infection; no direct daily-D3 fatigue finding was extracted.
      sourceKeys:
        - source_artifact:doi-10.3390-ijerph17051684
        - source_artifact:pmid-33847712
    -
      id: outcome-metrics-007-use-a-measurement-hierarchy-and-label-self-report-limits
      label: Use A Measurement Hierarchy And Label Self Report Limits
      stance: context_only
      summary: The page should use a measurement hierarchy: objective lab 25(OH)D as the primary measurable response; optional safety or clinical labs only when indicated; manual tests such as grip, sit-to-stand, timed-up-and-go, SPPB, gait, or BMD testing only when they match the user's context; and self-reported falls, URIs, mood, or fatigue as exploratory logs. Extracted falls and URI studies commonly used annual self-report, daily symptom diaries, semiannual surveys, or survey/diary subsets, while fracture outcomes require long follow-up or linked/trial-level event data.
      sourceKeys:
        - source_artifact:pmid-24014734
        - source_artifact:pmid-31923341
        - source_artifact:pmid-32492153
        - source_artifact:pmid-34337905
        - source_artifact:pmid-35939577
        - source_artifact:pmid-37011645
        - source_artifact:pmid-38113446
safety:
  cautionLevel: moderate
  avoidOrGetClinicianGuidance:
    - kidney_disease_or_reduced_function
    - kidney_stones
    - hypercalcemia_or_hypercalciuria
    - hyperparathyroidism
    - unexplained_calcium_or_pth_abnormality
    - sarcoidosis_or_granulomatous_disease
    - clinician_vitamin_d_calcium_warnings
    - pregnancy_trying_to_conceive_lactation
    - pediatric_or_adolescent_use
    - diagnosed_deficiency_clinician_managed
    - malabsorption_or_cystic_fibrosis
    - bariatric_surgery_or_short_bowel
    - intestinal_rehabilitation
    - current_d2_calcifediol_or_calcitriol
    - alfacalcidol_or_paricalcitol
    - prescription_or_high_dose_vitamin_d
    - weekly_monthly_or_bolus_schedules
    - uvb_or_fortified_food_protocols
    - high_dose_calcium_products
    - calcium_with_stone_or_ckd_risk
    - total_vitamin_d_above_4000_iu_per_day
    - unknown_total_intake_or_dose_uncertainty
  stopIf:
    - Symptoms suggesting hypercalcemia or kidney stone occur.
    - Seek urgent care for severe confusion, severe dehydration, persistent vomiting, inability to keep fluids down, severe flank pain, blood in urine, fever with stone symptoms, or rapidly worsening weakness.
    - Serum calcium is high, urine calcium is high, 25(OH)D is above the lab reference range or clinician concern threshold, kidney function worsens, or a clinician advises stopping.
    - A product error, recall, labeling concern, accidental high dose, compounded/repackaged product, or untracked supplement stack makes total vitamin D dose uncertain.
    - Total vitamin D intake may exceed 4000 IU/day.
    - Calcium products, calcifediol, active vitamin D analogues, prescription/high-dose vitamin D, weekly/monthly/bolus/loading schedules, or medication changes requiring calcium/kidney review are started.
    - A new kidney, calcium, urine-calcium, parathyroid, granulomatous, pregnancy/lactation, pediatric/adolescent, malabsorption/bariatric, clinician-flagged vitamin D/calcium risk, deficiency-treatment, or active-analogue context arises.
  notes:
    - 4000 IU/day is a safety ceiling, not a target.
    - Hypercalcemia and hypercalciuria are the main adverse signals — especially at upper-end doses or with calcium co-use.
    - Kidney-stone risk is context-dependent — D-only pooled evidence was null, but calcium-plus-D increased stones.
    - No named drug-interaction table supported here — keep medication and supplement review broad.
---
Daily Vitamin D3 Supplementation is a simple daily oral cholecalciferol experiment whose main measurable outcome is **serum 25(OH)D**. The useful question is whether a consistent daily D3 dose changes vitamin D status for this person under logged conditions, not whether vitamin D becomes a guaranteed cure or disease-prevention intervention.

## What this protocol is for

Use this protocol when the experiment is daily oral D3, low-risk adult self-tracking after a negative safety screen, and focused on 25(OH)D lab feedback. The strongest direct evidence supports a dose-related biomarker rise over weeks to months.

## What to track

Track dose, adherence, product, baseline and follow-up 25(OH)D with units, supplement stack, calcium products, sun or UV exposure, travel/latitude, season, diet or fortified-food changes, and symptoms that could suggest calcium or kidney-stone problems. Baseline status, body size, season, sun exposure, diet, and population context can all change the observed response.

## What not to overread

Do not promote a 25(OH)D rise as proof of better fractures, falls, respiratory outcomes, fatigue, mood, cardiovascular outcomes, or mortality. Those outcomes are mixed, long-horizon, population-dependent, or not well suited to a short personal experiment.

## Safety posture

Safety is stronger than efficacy when the dose, medical context, or supplement stack is uncertain. Treat adult upper-intake guidance as a ceiling rather than a target, and route kidney disease, stones, high serum or urine calcium, hyperparathyroidism, granulomatous-disease contexts, pregnancy/lactation, pediatric or adolescent use, malabsorption/bariatric contexts, deficiency treatment, calcifediol or active vitamin D analogues, non-daily schedules, high-dose calcium products, unknown total intake, or medication plans where calcium or kidney changes matter to clinician guidance.
